The drugmaker Moderna said, on Thursday (5), that the protection of its vaccine against covid-19 remains strong for at least six months and that the booster injection it is testing generated a “robust” antibody response against the delta variant.
In a recent review of their phase 3, or final phase, clinical trial, Moderna’s anti-covid vaccine was 93% effective at six months of the second dose.
+ Northeastern governors suspend purchase of Russian Sputnik V vaccine
The company is also conducting clinical trials with three different covid-19 boosters.
All of them produce high levels of antibodies against the original strain of coronavirus and the variants of interest, including delta, originally identified in India and very contagious.
“We are pleased that our covid-19 vaccine has a lasting efficacy of 93% at six months, but we recognize that the delta variant is an important new threat, so we must remain vigilant,” said Director General Stephane Bancel in an announcement.
The statement adds that Moderna hopes to submit its application for full approval of its anti-covid vaccine to the US Food and Drug Administration (FDA) this month. Until now, only its emergency use is authorized.
The company has also started studies for other vaccines, such as flu, Zika and respiratory syncytial virus, among others, and is developing a covid vaccine that can be stored at refrigerator temperature.
+ Learn about the effectiveness of each vaccine against Covid-19